WO2002039996A2 - Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists - Google Patents
Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists Download PDFInfo
- Publication number
- WO2002039996A2 WO2002039996A2 PCT/US2001/044161 US0144161W WO0239996A2 WO 2002039996 A2 WO2002039996 A2 WO 2002039996A2 US 0144161 W US0144161 W US 0144161W WO 0239996 A2 WO0239996 A2 WO 0239996A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- estramustine phosphate
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 229960004750 estramustine phosphate Drugs 0.000 title claims abstract description 43
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 title claims abstract description 41
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 31
- 239000000556 agonist Substances 0.000 title claims abstract description 27
- 239000005557 antagonist Substances 0.000 title claims abstract description 20
- 238000002648 combination therapy Methods 0.000 title description 5
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 claims abstract description 26
- 102100024028 Progonadoliberin-1 Human genes 0.000 claims abstract description 26
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 claims abstract description 26
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 241000124008 Mammalia Species 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 22
- 206010033128 Ovarian cancer Diseases 0.000 claims description 17
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 17
- 108010050144 Triptorelin Pamoate Proteins 0.000 claims description 15
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 229960004824 triptorelin Drugs 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 239000004475 Arginine Substances 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 206010060862 Prostate cancer Diseases 0.000 claims description 9
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 108010069236 Goserelin Proteins 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 6
- 108700008462 cetrorelix Proteins 0.000 claims description 6
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 6
- 229960003230 cetrorelix Drugs 0.000 claims description 6
- 229960002913 goserelin Drugs 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 5
- 241001132374 Asta Species 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 108010037003 Buserelin Proteins 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 4
- 229960002719 buserelin Drugs 0.000 claims description 4
- 208000037828 epithelial carcinoma Diseases 0.000 claims description 4
- -1 estramustine phosphate arginine salt Chemical class 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 230000002611 ovarian Effects 0.000 claims description 4
- 210000003101 oviduct Anatomy 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 108010000817 Leuprolide Proteins 0.000 claims description 3
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims description 3
- 229960004338 leuprorelin Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 2
- WDYSQADGBBEGRQ-APSDYLPASA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-[(2r,3r,4r,5r,6s) Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WDYSQADGBBEGRQ-APSDYLPASA-N 0.000 claims description 2
- HJNZCKLMRAOTMA-BRBGIFQRSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(2s)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(2-methyl-1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydr Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=C(C)NC2=CC=CC=C12 HJNZCKLMRAOTMA-BRBGIFQRSA-N 0.000 claims description 2
- PZUOEYPTQJILHP-GBXIJSLDSA-N (2s,3r)-2-amino-3-hydroxybutanamide Chemical compound C[C@@H](O)[C@H](N)C(N)=O PZUOEYPTQJILHP-GBXIJSLDSA-N 0.000 claims description 2
- 108700013943 AN 207 Proteins 0.000 claims description 2
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N Deslorelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 claims description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 2
- 108700029108 MI 1544 Proteins 0.000 claims description 2
- 108010021717 Nafarelin Proteins 0.000 claims description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 2
- 108010023617 abarelix Proteins 0.000 claims description 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 2
- 229960002184 abarelix Drugs 0.000 claims description 2
- 108010070670 antarelix Proteins 0.000 claims description 2
- 229950010887 avorelin Drugs 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 claims description 2
- 229960000766 danazol Drugs 0.000 claims description 2
- 108700025485 deslorelin Proteins 0.000 claims description 2
- 229960005408 deslorelin Drugs 0.000 claims description 2
- 108700032141 ganirelix Proteins 0.000 claims description 2
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims description 2
- 229960003794 ganirelix Drugs 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 claims description 2
- 229960002333 nafarelin Drugs 0.000 claims description 2
- 108010092834 ramorelix Proteins 0.000 claims description 2
- 229950000277 ramorelix Drugs 0.000 claims description 2
- 229950011372 teverelix Drugs 0.000 claims description 2
- XCRFEYAXJYXVHT-HLZMRHSNSA-N CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 XCRFEYAXJYXVHT-HLZMRHSNSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 239000000243 solution Substances 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical class [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940032510 trelstar Drugs 0.000 description 1
- 229960000294 triptorelin pamoate Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the present invention relates to the field of cancer treatment and provides a combination therapy for treating cancers in mammals, including humans, comprising the steps of administering estramustine phosphate and Luteinzing Hormone Releasing Hormone agonists or antagonists, hereinafter shortly referred to as LHRH agonists or antagonists, respectively.
- Estramustine phosphate is a known anti-mitotic agent currently used, in therapy, in the treatment of advanced adenocarcinoma of the prostate.
- estramustine phosphate either as a single agent or in combination therapies against a variety of tumor types see, for instance, the international patent application WO 99/49869, which is herewith incorporated by reference.
- LHRH agonists or antagonists are known therapeutic agents used in the treatment of hormone-dependent cancers such as, for instance, hormone-dependent breast and endometrial cancer.
- hormone-dependent cancers such as, for instance, hormone-dependent breast and endometrial cancer.
- prostatic adenocarcinoma, benign prostatic hypertrophy and hormone-dependent mammary tumors can be treated with various LHRH agonists and that prostate adenocarcinoma and benign hypertrophy can be treated by use of various LHRH agonists.
- the present invention also provides the use of estramustine phosphate, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancers in a patient undergoing a simultaneous, separate or sequential treatment with a LHRH agonist or antagonist.
- the invention also provides a product containing estramustine phosphate, or a pharmaceutically acceptable salt thereof, and a LHRH agonist or antagonist as a combined preparation for simultaneous, separate or sequential use in treating cancers.
- cancers examples include testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer, lung cancer, colorectal cancer, brain cancers and melanoma.
- cancers are prostate cancer, ovarian cancer and breast cancer.
- LHRH agonists are, e.g., leuprorelin, deslorelin, triptorelin, buserelin, nafarelin, goserelin, avorelin, histerelin, compound PTL 03001 (5-oxo-L- propyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L- prolinamide) (Peptech), compound AN 207 (6-[N6-[5-[2-[l,2,3,4,6,l l-hexahydro-2,5,12- trihydroxy-7-mehoxy-6, 11 -dioxo-4- [[2,3 ,6-trideoxy-3 -(2,3-dihydro- 1 H-pyrrol- 1 -yl) ⁇ -L-L-
- LHRH antagonists are e.g. cetrorelix, abarelix. ramorelix, teverelix, ganirelix, compounds A 75998 (Acetyl-D-(2-naphthyl)alanyl-D-(4- chlorophenyl)alanyl-D-(3- ⁇ yridyl)al-myl-seryl-(N-methyl)tyrosyl-N6-(nicotinoyl)-D-lysyl- leucyl-N6-(isopropyl)lysyl-propyl-D-alaninamide) and A 84861 (Tetrahydrofuran-2-(S)- ylcarbonyl-glycyl-D-(2-na ⁇ hthyl)alanyl-D-(4-choko)phenylalanyl-D-(3-pyridyl)-alanyl-L-(N
- the inventors of the present invention have also found that treatment of the above- mentioned cancers by combined administration of a therapeutically effective amount of estramustine phosphate, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a LHRH agonist or antagonist, can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of either sole estramustine phosphate or the sole LHRH agonist or antagonist.
- a therapeutically effective amount of estramustine phosphate, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a LHRH agonist or antagonist can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of either sole estramustine phosphate or the sole LHRH agonist or antagonist.
- such combined therapy provides a synergistic or superadditive therapeutic effect, without being paralleled by toxic effects.
- a superadditive or synergistic antitumor effect it is meant the inhibition of growth of a tumor, preferably the complete regression of the tumor, by administering a combination of estramustine phosphate and LHRH agonist or antagonist, to a mammal, including a human being, the result being advantageous compared to that obtained with the components of the combination when administered alone.
- the superadditive antitumor effect results in an anti-cancer therapy having increased effectiveness in controlling, i.e. slowing, interrupting, arresting, stopping or reversing, the neoplasm formation.
- controlling the growth of the neoplasm refers to slowing, interrupting, arresting or stopping its growth and it does not indicate, necessarily, a total elimination of the neoplasm.
- treating simply means that life expectancy of an individual affected with a cancer will be increased, one or more of the symptoms of the disease will be reduced and/or quality of life will be enhanced.
- estramustine phosphate and the LHRH agonist or antagonist can be administered in any form or mode which makes the compounds bioavailable in effective amounts, including oral and parenteral routes.
- administered or “administering” as used herein is meant any acceptable manner of administering a drug to a patient which is medically acceptable including parenteral and oral administration.
- parenteral is meant intravenous, subcutaneous, intradermal or intramuscular administration.
- Oral administration includes administering one or both of the constituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
- the actual method and order of administration of the combined preparations of the invention can vary according to, inter alia, the particular pharmaceutical formulation of the estramustine phosphate derivative being used, the particular pharmaceutical fonnulation of the
- LHRH agonist or antagonist being used, the particular cancer to be treated and the conditions of the patient being treated.
- estramustine phosphate derivative in the combined method of treatment according to the subject invention, can be administered simultaneously with the LHRH agonist or antagonist or the compounds can be administered sequentially, in either order.
- the dosage ranges for the administration of the combined preparation can vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.
- the dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associated treatments in a manner that is conventional for any therapy, and can be adjusted in response to changes in conditions and/or in light of other clinical conditions.
- estramustine phosphate can be administered orally or parenterally, through a central or peripheral intravenous route. According to one embodiment, it is administered at dosages, per single intravenous infusion, exceeding 1300 mg or 950 mg/m 2 .
- the solution intended for injection, for instance containing estramustine phosphate as meglunine salt, is then given as intravenous infusion with the preferred duration of infusion time varying from about 30 minutes to 3 hours.
- estramustine phosphate When estramustine phosphate is administered through a peripheral intravenous route, a longer duration of infusion and greater total infusional volume can be utilized to minimize vascular irritation.
- the estramustine phosphate solution can also be mixed with various amounts of human albumin plasma proteins, cyclodextrins and amino acids, for instance arginine, so as to minimize any potential vascular damage.
- estramustine phosphate can be intravenously administered together with arginine in different ratios, also including estramustine phosphate arginine salt.
- estramustine phosphate When estramustine phosphate is administered through a central venous route, the administration can be performed through either a temporary or permanent venous access device, according to conventional methods.
- estramustine phosphate can be orally administered, for instance as disodium salt, in the form of capsules or tablets.
- estramustine phosphate disodium salt can be thus conveniently administered in solid oral dosage forms also containing cyclodextrin and derivatives thereof.
- LHRH agonist or antagonist is in general the one commonly used in therapy for such compounds.
- cetrorelix can be administered as single intramuscular administration of slow release cetrorelix 60 mg followed by a second injection after 24 hours then 60 mg every 3-4 weeks.
- Goserelin can be administered as goserelin acetate by subcutaneous administration of slow release goserelin at a dosage from about 3 to about 12 mg.
- Triptorelin can be administered for instance as triptorelin pamaote by intramuscular administration of long acting formulation, such as 1, 2, 3 or 4 months depot triptorelin formulat on at a dosage from about 3 to about 20 mg.
- triptorelin parnoate can be intramuscularly administered in the form of microparticles as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885, and more specifically as Trelstar® 1 -month Depot formulation 3.75 mg.
- Another embodiment of the invention comprises a method of treating a cancer selected from prostate, ovarian and breast cancer in a mammal in need of such treatment, comprising administering substantially simultaneously to said mammal estramustine phosphate and triptorelin or a pharmaceutically acceptable salt thereof, in amounts and close in time sufficient to achieve a therapeutically useful effect.
- An additional embodiment of the invention provides the use of estramustine phosphate in the manufacture of a medicament for treating a cancer selected from prostate, ovarian and breast cancer in a mammal, undergoing a substantially simultaneous treatment with triptorelin or a pharmaceutically acceptable salt thereof.
- kits or single packages combining the pharmaceutical compositions useful for the combination treatment of the selected cancers discussed above.
- the kits or packages can also contain instructions to use the pharmaceutical compositions in accordance with the present invention.
- a pharmaceutical composition for intramuscular administration containing triptorelin pamoate in the form of Treltar® Depot can be prepared as described in US Pat. No.
- estramustine phosphate can be prepared as described in the aforementioned WO 99/49869.
- estramustine phosphate arginine formulations can be prepared as follows:
- estramustine phosphate 300 mg were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 101 mg of arginine base were then added to the watery dispersion of the active whilst maintaining under stirring until a clear solution was obtained. The prepared solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 10.1 mg ml of arginine (1:1 molar ratio respectively).
- estramustine phosphate 300 mg were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 202 mg of arginine base were then added to the watery dispersion of the active whilst maintaining under stirring until a clear solution was obtained.
- the basic pH of the obtained solution was brought to the physiological value of about 7.5 by slow addition of diluted hydrochloric acid.
- the solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 20.2 mg/ml of arginine (1:2 molar ratio respectively).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A method for treating tumors in a mammal, including humans, in need of such a treatment including administering simultaneously, separately or sequentially to said mammal estramustine phosphate and a LHRH agonist or antagonist, in amounts sufficient to achieve a therapeutically useful effect.
Description
COMBINED THERAPY AGAINST TUMORS COMPRISING ESTRAMUSTINE PHOSPHATE AND LHRH AGONISTS OR ANTAGONISTS
FIELD OF THE INVENTION
The present invention relates to the field of cancer treatment and provides a combination therapy for treating cancers in mammals, including humans, comprising the steps of administering estramustine phosphate and Luteinzing Hormone Releasing Hormone agonists or antagonists, hereinafter shortly referred to as LHRH agonists or antagonists, respectively.
BACKGROUND OF THE INVENTION
Estramustine phosphate is a known anti-mitotic agent currently used, in therapy, in the treatment of advanced adenocarcinoma of the prostate. For a general reference to estramustine phosphate, either as a single agent or in combination therapies against a variety of tumor types see, for instance, the international patent application WO 99/49869, which is herewith incorporated by reference.
LHRH agonists or antagonists are known therapeutic agents used in the treatment of hormone-dependent cancers such as, for instance, hormone-dependent breast and endometrial cancer. As an example, in U.S. Pat. No. 4,472,382 it is disclosed that prostatic adenocarcinoma, benign prostatic hypertrophy and hormone-dependent mammary tumors can be treated with various LHRH agonists and that prostate adenocarcinoma and benign hypertrophy can be treated by use of various LHRH agonists.
Some clinical improvement in pre-menopausal women with breast cancer by use of the two LHRH agonists, Buserelin and Leuprolide, is also reported by H. A. Harvey et al. "LH-RH analogs in the treatment of human breast cancer", LHRH and its Analogs - A new Class of contraceptive and therapeutic Agents (B. H. Nickery and J. J. Nestor, J., and E. S. E. Hafez, eds) Lancaster, MTP Press, (1984) and the J. G. M. Klijn et al., "Treatment with luteinizing hormone-relating hormone analogue (Buserelin) in premenopausal patients with metastatic breast cancer", Lancet 1, 1213-1216 (1982).
It is thus a first object of the present invention to provide a therapeutic method for treating tumors in a mammal in need of such a treatment, including humans, comprising administering simultaneously, separately or sequentially to said mammal estramustine phosphate, or a pharmaceutically acceptable salt thereof, and a LHRH agonist or antagonist, in amounts and close in time sufficient to achieve a therapeutic useful effect.
The present invention also provides the use of estramustine phosphate, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating cancers in a patient undergoing a simultaneous, separate or sequential treatment with a LHRH agonist or antagonist.
The invention also provides a product containing estramustine phosphate, or a pharmaceutically acceptable salt thereof, and a LHRH agonist or antagonist as a combined preparation for simultaneous, separate or sequential use in treating cancers.
Examples of such cancers are testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer, lung cancer, colorectal cancer, brain cancers and melanoma. In one embodiment of the invention, such cancers are prostate cancer, ovarian cancer and breast cancer.
Examples of LHRH agonists according to the invention are, e.g., leuprorelin, deslorelin, triptorelin, buserelin, nafarelin, goserelin, avorelin, histerelin, compound PTL 03001 (5-oxo-L- propyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L- prolinamide) (Peptech), compound AN 207 (6-[N6-[5-[2-[l,2,3,4,6,l l-hexahydro-2,5,12- trihydroxy-7-mehoxy-6, 11 -dioxo-4- [[2,3 ,6-trideoxy-3 -(2,3-dihydro- 1 H-pyrrol- 1 -yl)α-L-lyxo- hexopyranosyl] oxy] -2-naphthacenyl] -1,5 -dioxopentyl] -D-lysine] -,(2S-cis)-) (ASTA Medica Inc.), compound AN 238 L-threoninamide, N-[5-[2-[(2S,4S)-l,2,3,4,6,ll-hexahydro-2,5,12- trihydroxy-7-methoxy-6, 11 -dioxo-4-[[2,3 ,6-trideoxy-3 -(2,3 -dihydro- 1 H-pyrrl- 1 -yl)α-L-lyxo- hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethoxy]-l,5-dioxopentyl]-D-phenylalanyl-L- cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2 7)-disulfide (ASTA Medica Inc.), compound AN 201, compound SPD 424 (LHRH-hydrogel implant) (Shire Pharmaceuticals Group) compound TX 397 (Theramex SAM), and danazol, or a pharmaceutically acceptable salt thereof. In one embodiment of the invention, LHRH agonists
are triptorelin and goserelin, or a pharmaceutically acceptable salt thereof, in particular triptorelin or a pharmaceutically acceptable salt thereof.
Examples of LHRH antagonists, according to the invention, are e.g. cetrorelix, abarelix. ramorelix, teverelix, ganirelix, compounds A 75998 (Acetyl-D-(2-naphthyl)alanyl-D-(4- chlorophenyl)alanyl-D-(3-ρyridyl)al-myl-seryl-(N-methyl)tyrosyl-N6-(nicotinoyl)-D-lysyl- leucyl-N6-(isopropyl)lysyl-propyl-D-alaninamide) and A 84861 (Tetrahydrofuran-2-(S)- ylcarbonyl-glycyl-D-(2-naρhthyl)alanyl-D-(4-choko)phenylalanyl-D-(3-pyridyl)-alanyl-L-(N- methyl)tyrosyl-D-[N6-(3-pyridylcarbonyl)]lysyl-L-leucyl-L-(N6-isopropyl)lysyl-L-propyl-D- alanylamide) (Abbot Labs.), compound PM-ON-92 (Protherics), GnRH immunogen (Aphton Co.), compound D 26344 (ASTA Medica), compound T 98475 (Isopropyl 3-(Ν-benzyl-Ν- methylaminomethyl)-7-(2,6-difluorobenzyl)-4,7-dihydro-2-(4-isobutyrylaminoρhenyl)-4- oxothieno[2,3-bpyridine-5-carboxylate hydrochloride) (Takeda), and compound MI 1544 (Acetyl-D-tryptophyl-D-cyclopropyl-alanyl-D-tryptophyl-L-seryl-L-tyrosyl-D-lysyl-L-leucyl- L-arginyl-L-propyl-D-alaninamide), or a pharmaceutically acceptable salt thereof. In one embodiment, a LHRH antagonist is cetrorelix or a pharmaceutically acceptable salt thereof.
The inventors of the present invention have also found that treatment of the above- mentioned cancers by combined administration of a therapeutically effective amount of estramustine phosphate, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a LHRH agonist or antagonist, can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of either sole estramustine phosphate or the sole LHRH agonist or antagonist. Namely, such combined therapy provides a synergistic or superadditive therapeutic effect, without being paralleled by toxic effects.
By the term "a superadditive or synergistic antitumor effect", as used herein, it is meant the inhibition of growth of a tumor, preferably the complete regression of the tumor, by administering a combination of estramustine phosphate and LHRH agonist or antagonist, to a mammal, including a human being, the result being advantageous compared to that obtained with the components of the combination when administered alone.
hi one embodiment of the invention, the superadditive antitumor effect results in an anti-cancer therapy having increased effectiveness in controlling, i.e. slowing, interrupting,
arresting, stopping or reversing, the neoplasm formation.
As used herein, "controlling the growth" of the neoplasm refers to slowing, interrupting, arresting or stopping its growth and it does not indicate, necessarily, a total elimination of the neoplasm.
Therefore, the term "treating" simply means that life expectancy of an individual affected with a cancer will be increased, one or more of the symptoms of the disease will be reduced and/or quality of life will be enhanced.
Method and Administration hi effecting treatment of a patient in a therapy method according to the invention, the estramustine phosphate and the LHRH agonist or antagonist can be administered in any form or mode which makes the compounds bioavailable in effective amounts, including oral and parenteral routes.
By the term "administered" or "administering" as used herein is meant any acceptable manner of administering a drug to a patient which is medically acceptable including parenteral and oral administration.
By "parenteral" is meant intravenous, subcutaneous, intradermal or intramuscular administration. Oral administration includes administering one or both of the constituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
The actual method and order of administration of the combined preparations of the invention can vary according to, inter alia, the particular pharmaceutical formulation of the estramustine phosphate derivative being used, the particular pharmaceutical fonnulation of the
LHRH agonist or antagonist being used, the particular cancer to be treated and the conditions of the patient being treated.
In the combined method of treatment according to the subject invention, the estramustine phosphate derivative can be administered simultaneously with the LHRH agonist or antagonist or the compounds can be administered sequentially, in either order.
Dosage
The dosage ranges for the administration of the combined preparation can vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.
The dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associated treatments in a manner that is conventional for any therapy, and can be adjusted in response to changes in conditions and/or in light of other clinical conditions.
According to the invention, estramustine phosphate can be administered orally or parenterally, through a central or peripheral intravenous route. According to one embodiment, it is administered at dosages, per single intravenous infusion, exceeding 1300 mg or 950 mg/m2. The solution intended for injection, for instance containing estramustine phosphate as meglunine salt, is then given as intravenous infusion with the preferred duration of infusion time varying from about 30 minutes to 3 hours.
When estramustine phosphate is administered through a peripheral intravenous route, a longer duration of infusion and greater total infusional volume can be utilized to minimize vascular irritation. The estramustine phosphate solution can also be mixed with various amounts of human albumin plasma proteins, cyclodextrins and amino acids, for instance arginine, so as to minimize any potential vascular damage.
Advantageously, estramustine phosphate can be intravenously administered together with arginine in different ratios, also including estramustine phosphate arginine salt.
When estramustine phosphate is administered through a central venous route, the administration can be performed through either a temporary or permanent venous access device, according to conventional methods.
Alternatively, estramustine phosphate can be orally administered, for instance as disodium salt, in the form of capsules or tablets. According to an alternative embodiment of the invention, estramustine phosphate disodium salt can be thus conveniently administered in solid
oral dosage forms also containing cyclodextrin and derivatives thereof. For a general reference to the administration of estramustine phosphate disodium salt and cyclodextrin see the
International patent application WO 96/09072, in the name of Pharmacia AB, and herewith incorporated by reference.
An effective amount of LHRH agonist or antagonist is in general the one commonly used in therapy for such compounds. For instance, cetrorelix can be administered as single intramuscular administration of slow release cetrorelix 60 mg followed by a second injection after 24 hours then 60 mg every 3-4 weeks. Goserelin can be administered as goserelin acetate by subcutaneous administration of slow release goserelin at a dosage from about 3 to about 12 mg. Triptorelin can be administered for instance as triptorelin pamaote by intramuscular administration of long acting formulation, such as 1, 2, 3 or 4 months depot triptorelin formulat on at a dosage from about 3 to about 20 mg. In particular triptorelin parnoate can be intramuscularly administered in the form of microparticles as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885, and more specifically as Trelstar® 1 -month Depot formulation 3.75 mg.
Another embodiment of the invention comprises a method of treating a cancer selected from prostate, ovarian and breast cancer in a mammal in need of such treatment, comprising administering substantially simultaneously to said mammal estramustine phosphate and triptorelin or a pharmaceutically acceptable salt thereof, in amounts and close in time sufficient to achieve a therapeutically useful effect.
An additional embodiment of the invention provides the use of estramustine phosphate in the manufacture of a medicament for treating a cancer selected from prostate, ovarian and breast cancer in a mammal, undergoing a substantially simultaneous treatment with triptorelin or a pharmaceutically acceptable salt thereof.
As stated above, the invention also provides kits or single packages combining the pharmaceutical compositions useful for the combination treatment of the selected cancers discussed above. The kits or packages can also contain instructions to use the pharmaceutical compositions in accordance with the present invention.
A pharmaceutical composition for intramuscular administration containing triptorelin pamoate in the form of Treltar® Depot can be prepared as described in US Pat. No.
5,225,205 and US Pat. No. 5,776,885, herein incorporated by reference. A pharmaceutical composition for intravenous use comprising estramustine phosphate can be prepared as described in the aforementioned WO 99/49869.
As an additional example, estramustine phosphate arginine formulations can be prepared as follows:
Example 1
Preparation of estramustine phosphate arginine salt (estramustine phosphate :arginine=l:l molar ratio) formulation for injection
300 mg of estramustine phosphate were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 101 mg of arginine base were then added to the watery dispersion of the active whilst maintaining under stirring until a clear solution was obtained. The prepared solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 10.1 mg ml of arginine (1:1 molar ratio respectively).
Example 2
Preparation of estramustine phosphate arginine salt in admixture with arginine (estramustine phosphate:argmme=l:2 molar ratio) formulation for injection
300 mg of estramustine phosphate were weighed in a beaker and dispersed by means of magnetic stirring in 5 ml of water. 202 mg of arginine base were then added to the watery dispersion of the active whilst maintaining under stirring until a clear solution was obtained.
The basic pH of the obtained solution was brought to the physiological value of about 7.5 by slow addition of diluted hydrochloric acid.
The solution was then brought to the final volume of 10 ml with water so as to reach a final concentration of 30 mg/ml of estramustine phosphate and 20.2 mg/ml of arginine (1:2 molar ratio respectively).
Claims
1. A method for treating tumors in a mammal, including humans, in need of such a treatment comprising administering simultaneously, separately or sequentially to said mammal estramustine phosphate, or a pharmaceutically acceptable salt thereof, and a LHRH agonist or antagonist, in amounts sufficient to achieve a therapeutically useful effect.
2. A method according to claim 1, wherein the mammal is a human
3. A method according to claim 1, wherein the tumor is selected from the group consisting of testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer, lung cancer, colorectal cancer, brain cancers and melanoma.
4. A method according to claim 3, wherein the tumor is selected from the group consisting of prostate, ovarian and breast cancer.
5. A method according to claim 1, wherein the LHRH agonist is selected from the group consisting of leuprorelin, deslorelin, triptorelin, buserelin, nafarelin, goserelin, avorelin, histerelin, compound PTL 03001 (5-oxo-L-propyl-L-histidyl-L-tryptophyl-L-seryl-L- tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide), compound AN 207 (6- [N6-[5-[2-[l,2,3,4,6,ll-hexahydro-2,5,12-trihydroxy-7-mehoxy-6,ll-dioxo-4-[[2,3,6- trideoxy-3-(2,3-dihydro-lH-pyrrol-l-yl)α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-l,5- dioxopentyl]-D-lysine]-,(2S-cis)-), compound AN 238 L-threoninamide, N-[5-[2-[(2S,4S 1,2,3,4,6,1 l-hexaliydro-2,5,12-trihydroxy-7-methoxy-6,l l-dioxo-4-[[2,3,6-trideoxy-3-(2,3- dihydro- 1 H-pyrrl- 1 -yl)α-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoethoxy]- 1,5- dioxopentyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryρtophyl-L-lysyl-L-valyl-L- cysteinyl-, cyclic (2 7)-disulfϊde, compound AN 201, compound SPD 424 (LHRH- hydrogel implant), compound TX 397 (Theramex SAM), danazol, and a pharmaceutically acceptable salt thereof.
6. A method according to claim 5, wherein the LHRH agonist is selected from the group consisting of triptorelin, goserelin and the pharmaceutically acceptable salts thereof.
7. A method according to claim 1, wherein the LHRH antagonist is selected from the group consisting of cetrorelix, abarelix, ramorelix, teverelix, ganirelix, compound A 75998
(Acetyl-D-(2-naphthyl)alanyl-D-(4-chlorophenyl)alanyl-D-(3-pyridyl)alanyl-seryl-(N- methyl)tyrosyl-N6-(nicotinoyl)-D-lysyl-leucyl-N6-(isopropyl)lysyl-propyl-D-alaninamide), A 84861 (Tetrahydrofuran-2-(S)-ylcarbonyl-glycyl-D-(2-naphthyl)alanyl-D-(4- cholro)phenylalanyl-D-(3-pyridyl)-alanyl-L-(N-methyl)tyrosyl-D-[N6-(3- pyridylcarbonyl)]lysyl-L-leucyl-L-(N6-isopropyl)lysyl-L-proρyl-D-alanylamide), compound PM-ON-92 (Protherics), GnRH immunogen, compound D 26344 (ASTA
Medica), compound T 98475 (Isopropyl 3-(Ν-benzyl-Ν-methylaminomethyl)-7-(2,6- difluorobenzyl)-4,7-dihydro-2-(4-isobutyrylaminoρhenyl)-4-oxothieno[2,3-bpyridine-5- carboxylate hydrochloride), compound MI 1544 (Acetyl-D-tryptophyl-D-cyclopropyl- alanyl-D-tryptophyl-L-seryl-L-tyrosyl-D-lysyl-L-leucyl-L-arginyl-L-propyl-D- alaninamide), and a pharmaceutically acceptable salt thereof.
8. A method according to claim 7, wherein the LHRH antagonist is cetrorelix or pharmaceutically acceptable salts thereof.
9. A method according to claim 1, wherein estramustine phosphate, or a pharmaceutically acceptable salt thereof, is administered intravenously.
10. A method according to claim 9, wherein estramustine phosphate is administered intravenously at dosages, per single infusion, exceeding 1300 mg or 950 mg/m2.
11. A method according to claim 9, wherein estramustine phosphate is administered intravenously as estramustine phosphate arginine salt or as estramustine phosphate meglumine salt with arginine.
12. A method according to claim 1, wherein estramustine phosphate, or a pharmaceutically acceptable salt thereof, is administered orally.
13. A method according to claim 1, wherein estramustine phosphate is in the form of estrmustine phosphate disodium salt.
14. Use of estramustine phosphate, or of a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a cancer selected from the group consisting of testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer, lung cancer, colorectal cancer, brain cancers and melanoma, in a mammal undergoing a substantially simultaneous treatment with a LHRH agonist or antagonist.
15. Use according to claim 14, wherein the mammal is a human.
16. Use according to claim 14, wherein the LHRH agonist or antagonist is triptorelin.
17. Use according to claim 14, wherein the cancer is selected from the group consisting of prostate, ovarian and breast cancer.
18. Products comprising estramustine phosphate, or a pharmaceutically acceptable salt thereof, and a LHRH agonist or antagonist, as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.
19. Products comprising estramustine phosphate, or a pharmaceutically acceptable salt thereof, and triptorelin, as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.
20. Products according to claim 17, wherein the tumors are selected from the group consisting of testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer, lung cancer, colorectal cancer, brain cancers and melanoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2002228648A AU2002228648A1 (en) | 2000-11-16 | 2001-11-06 | Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71460600A | 2000-11-16 | 2000-11-16 | |
| US09/714,606 | 2000-11-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2002039996A2 true WO2002039996A2 (en) | 2002-05-23 |
| WO2002039996A3 WO2002039996A3 (en) | 2003-03-20 |
Family
ID=24870732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2001/044161 WO2002039996A2 (en) | 2000-11-16 | 2001-11-06 | Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002228648A1 (en) |
| WO (1) | WO2002039996A2 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005041981A1 (en) * | 2003-10-31 | 2005-05-12 | Kurume University | Combination therapy of peptide vaccination and estramustine treatment |
| JP2007051066A (en) * | 2003-10-31 | 2007-03-01 | Univ Kurume | Combination therapy of peptide vaccine administration and estramustine treatment |
| US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| US10188670B2 (en) | 2011-03-15 | 2019-01-29 | Phosphagenics Limited | Composition |
| US11753435B2 (en) | 2016-12-21 | 2023-09-12 | Avecho Biotechnology Limited | Process |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002950713A0 (en) | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
| BRPI0613346A2 (en) | 2005-06-17 | 2011-01-04 | Vital Health Sciences Pty Ltd | vehicle for the administration of biologically active compounds, use of one or more c1-C4 alcohols, polyols and polymers thereof, water and one or more electron transfer complex di- and / or monophosphate derivatives thereof , vehicle preparation process, formulation, formulation preparation method, method of administering biologically active compounds |
| MX2012011355A (en) | 2010-03-30 | 2012-11-30 | Phosphagenics Ltd | Transdermal delivery patch. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795882A (en) * | 1992-06-22 | 1998-08-18 | Bone Care International, Inc. | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations |
| US5763429A (en) * | 1993-09-10 | 1998-06-09 | Bone Care International, Inc. | Method of treating prostatic diseases using active vitamin D analogues |
-
2001
- 2001-11-06 WO PCT/US2001/044161 patent/WO2002039996A2/en not_active Application Discontinuation
- 2001-11-06 AU AU2002228648A patent/AU2002228648A1/en not_active Abandoned
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005041981A1 (en) * | 2003-10-31 | 2005-05-12 | Kurume University | Combination therapy of peptide vaccination and estramustine treatment |
| WO2005041982A1 (en) * | 2003-10-31 | 2005-05-12 | Kurume University | Combination therapy of peptide vaccination and estramustine treatment |
| JP2007051066A (en) * | 2003-10-31 | 2007-03-01 | Univ Kurume | Combination therapy of peptide vaccine administration and estramustine treatment |
| US10071030B2 (en) | 2010-02-05 | 2018-09-11 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
| US10188670B2 (en) | 2011-03-15 | 2019-01-29 | Phosphagenics Limited | Composition |
| US11753435B2 (en) | 2016-12-21 | 2023-09-12 | Avecho Biotechnology Limited | Process |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002228648A1 (en) | 2002-05-27 |
| WO2002039996A3 (en) | 2003-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gonzalez‐Barcena et al. | Responses to the antagonistic analog of LH‐RH (SB‐75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer | |
| US5985877A (en) | Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer | |
| Schally et al. | Discovery of LHRH and development of LHRH analogs for prostate cancer treatment | |
| KR101795643B1 (en) | Composition for the treatment of prostate cancer | |
| EP1404357B1 (en) | Gonadotropin releasing hormone antagonist in gel-forming concentrations | |
| MXPA04009455A (en) | Enhancement of endogenous gonadotropin production. | |
| EP1891964A1 (en) | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits | |
| RU2002134463A (en) | PHARMACEUTICAL FORM FOR PARENTERAL INTRODUCTION AND METHOD FOR ITS PRODUCTION (OPTIONS) | |
| CA2348167A1 (en) | Pharmaceutical administration form for peptides, process for its preparation, and use | |
| WO2002039996A2 (en) | Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists | |
| AU2002230464A1 (en) | Combination therapy for estrogen-dependent disorders | |
| CN114903902A (en) | Application of GnRH receptor antagonist and androgen receptor antagonist in preparation of medicine for treating prostatic cancer | |
| Gonzalez‐Barcena et al. | Inhibition of the pituitary‐gonadal axis by a single intramuscular administration of D‐Trp‐6‐LH‐RH (Decapeptyl) in a sustained‐release formulation in patients with prostatic carcinoma | |
| US20040043938A1 (en) | Combination therapy for estrogen-dependent disorders | |
| EP3784346A1 (en) | A composition for treating one or more estrogen related diseases | |
| Forti | Clinicai applications of GnRH analogs | |
| Adegoke et al. | GnRH Antagonists in the Treatment of Uterine Fibroids | |
| Van Steenbrugge et al. | Administration of an LHRH-antagonist to male mice: effects on in vivo secretion of hormones and on the growth of a transplantable human prostatic carcinoma | |
| Decreased | 7 1ses | |
| HU199694B (en) | Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives | |
| KR20020059405A (en) | Formulations for parenteral use of estramustine phosphate with improved pharmacological properties | |
| KR100210472B1 (en) | Progesterone Hormone Secretion Hormone Antagonist Peptide | |
| Vet—QL02AA04 | Fosfestrol Sodium (BANM, rINNM) | |
| EP1092438A1 (en) | Pharmaceutical compositions containing growth-hormone inhibitors or their biologically active fragments for the treatment of uterine myomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |